JPMorgan downgraded InnovAge (INNV) to Underweight from Neutral with a $5 price target The company operates within a sensitive market and is subject to higher scrutiny from both state and federal regulators, which has presented an extended headwind to growth prospects over the past three years, the analyst tells investors in a research note. The firm cites lingering headwinds to InnovAge’s long-term growth prospects presented by regulatory scrutiny from both state and federal regulators for the downgrade.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on INNV:
- InnovAge reports helping 24,400 seniors with PACE since inception
- InnovAge Holding Corp. Reports Q1 Financial Results
- InnovAge reports Q1 EPS (4c), consensus (4c)
- InnovAge backs FY25 revenue view $815M-$865M, consensus $844.27M
- InnovAge Holding Strengthens Leadership with Key Appointments
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
